Extension of esketamine study shows long‐term safety in treatment‐resistant depression
The Brown University Psychopharmacology Update June 1, 2026 DOI: 10.1002/pu.31451 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Extension study Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Intervention | Esketamine nasal spray |
| Duration | Two-year extension |
| Topics | Depression Esketamine |
| Key points | No new safety concerns emerged with long-term esketamine use, and the overall relapse rate across the original trial and extension was 6.9%. |
Abstract
A two‐year extension of a trial of esketamine nasal spray in patients with treatment‐resistant depression has found no new safety concerns associated with long‐term use of the drug. The overall relapse rate across both the original trial and the extension was 6.9%.